Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced the appointment of Eilon Elmalem as site head of its wholly owned subsidiary Scinai Biopharma Services’ Yavne CDMO facility, effective June 14, 2026. Elmalem, who has supported the company as an external consultant for the past two years, brings more than two decades of biotechnology and pharmaceutical operations experience and will oversee site operations and engineering activities as Scinai continues expanding its contract development and manufacturing platform.
Elmalem’s appointment marks a strategic move to strengthen the leadership at Scinai’s CDMO operations. The company has been actively expanding its capabilities in contract development and manufacturing, a sector that has seen growing demand as biopharmaceutical companies seek external partners for production. With his extensive background, Elmalem is expected to drive operational excellence and support the scaling of manufacturing processes at the Yavne facility.
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies. The company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l. In addition to its drug development activities, Scinai owns Scinai Biopharma Services Ltd., a contract development and manufacturing organization that provides development and manufacturing services to biotechnology and pharmaceutical companies.
The Yavne facility is a key asset in Scinai’s CDMO business, and the appointment of a seasoned leader like Elmalem signals the company’s commitment to enhancing its service offerings and operational capabilities. As the biopharmaceutical industry continues to rely on CDMOs for efficient and scalable production, Scinai is positioning itself to capture a larger share of this market. The company’s dual focus on its own pipeline and CDMO services provides a diversified business model that could mitigate risks associated with drug development.
Investors and industry observers will be watching how Elmalem’s leadership impacts the Yavne facility’s performance and Scinai’s overall growth trajectory. The company’s latest news and updates are available in the company’s newsroom at https://ibn.fm/SCNI. For more information about Scinai Immunotherapeutics, visit the company’s website or refer to the full press release at https://ibn.fm/VLt3w.
